Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00325728 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 2
- Development phase
- 74
- Enrollment target
NCT00325728 is a Phase 2 study that has completed, run by Takeda. The registered enrollment target is 74 participants.
The verdict
NCT00325728, a Phase 2 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 74 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy of ramelteon, once daily (QD), in subjects with mild to moderate Alzheimer's Disease and sleep disturbance
Interventions
- DRUG Placebo
- DRUG Ramelteon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2006-03-21 |
| Est. Completion | 2007-08-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00325728
The ClinicalTrials.gov registry entry for NCT00325728 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00325728 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00325728 about?
NCT00325728 is a clinical study titled "Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's Disease". The purpose of this study is to determine the efficacy of ramelteon, once daily (QD), in subjects with mild to moderate Alzheimer's Disease and sleep disturbance
What is the current status of trial NCT00325728?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2006-03-21. Estimated completion is 2007-08-20.
What interventions are being tested in trial NCT00325728?
The interventions under investigation include: Placebo (DRUG), Ramelteon (DRUG).
Who is sponsoring clinical trial NCT00325728?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.